AI-powered polyp detector gains CE certification

Michael Walter | | Health Exec | Economics

PENTAX Medical, a division of the HOYA Group focused on endoscopic solutions, has received CE mark approval for its AI-powered polyp detector.

The solution, DISCOVERY, assists endoscopists by automatically seeking out signs of potential polyps. It was developed by a team at PENTAX Medical’s Augsburg, Germany-based research facility using data from approximately 300 clinical cases.

“The benefits for the customers are outstanding,” Wolfgang Mayer, managing director or research and development for PENTAX Medical Augsburg, said in a prepared statement. “Our vision was to bring artificial intelligence into the operating room in the most user-friendly way. We wanted to give doctors the possibility to use this exciting new technology to strive for a better clinical outcome and maximize the patient care.”

The company aims to begin launching DISCOVERY in early 2020.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.